1. Home
  2. TCPC vs BCYC Comparison

TCPC vs BCYC Comparison

Compare TCPC & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock TCP Capital Corp.

TCPC

BlackRock TCP Capital Corp.

HOLD

Current Price

$4.22

Market Cap

407.2M

Sector

Finance

ML Signal

HOLD

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

HOLD

Current Price

$4.68

Market Cap

360.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCPC
BCYC
Founded
2006
2009
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
407.2M
360.7M
IPO Year
2006
2019

Fundamental Metrics

Financial Performance
Metric
TCPC
BCYC
Price
$4.22
$4.68
Analyst Decision
Sell
Buy
Analyst Count
2
10
Target Price
$3.50
$13.90
AVG Volume (30 Days)
1.0M
371.9K
Earning Date
05-07-2026
05-01-2026
Dividend Yield
18.36%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.43
$4.24
52 Week High
$8.05
$9.55

Technical Indicators

Market Signals
Indicator
TCPC
BCYC
Relative Strength Index (RSI) 58.36 41.03
Support Level $3.43 $4.24
Resistance Level $4.49 $5.41
Average True Range (ATR) 0.14 0.20
MACD 0.03 -0.02
Stochastic Oscillator 63.95 2.00

Price Performance

Historical Comparison
TCPC
BCYC

About TCPC BlackRock TCP Capital Corp.

BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Share on Social Networks: